Classification and Manufacturing Model of Advanced Therapy Medicinal Products

Main Article Content

Patcharaphun kidpun
Rapeepun Chalongsuk

Article Details

How to Cite
kidpun P, Chalongsuk R. Classification and Manufacturing Model of Advanced Therapy Medicinal Products. Thai Food and Drug J [Internet]. 2021 Oct. 14 [cited 2024 Jun. 23];28(3):4-9. Available from:
Review Article


1. European Medicines Agency. Regulation (EC) No 1394/2007 of the European Parliament and of the Council [Internet]. Official Journal of the European Union. 2007 [cited 2019 May 9]. Available from:

2. United State Food and Drug Administration. Regulating Biological Products [Internet]. Silver Spring MD: U.S. FDA; 2008 [cited 2019 May 9]. Available from:

3. Azuma K. Regulatory landscape of regenerative medicine in Japan. Current Stem Cell Rep 1 2015;1:118-28. doi:

4. กระทรวงสาธารณสุข.ประกาศสำนักงานคณะกรรมการอาหารและยา เรื่อง แนวทางการขึ้นทะเบียนตำรับยาที่เป็นผลิตภัณฑ์การแพทย์ขั้นสูง ชนิดผลิตภัณฑ์เซลล์บำบัด. ราชกิจจานุเบกษา เล่มที่ 135, ตอนพิเศษ 302 ง (ลงวันที่ 28 พฤศจิกายน 2561).

5. Azmi B, Inglefield CJ, Lewis MP. Autologous cell therapy: current treatments and future prospects. Wounds 2009;21(9):234-42. PMID: 25903815.

6. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 2016;3:16015. doi: 10.1038/mto.2016.15.

7. Bonini C, Mondino A. Adoptive T-cell therapy for cancer: the era of engineered T cells. Eur J Immunol 2015;45(9):2457-69. doi: 10.1002/eji.201545552. PMID: 26202766.

8. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018;359:1361-5. doi: 10.1126/science.aar6711. PMID: 29567707.

9. Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014;99:361-71. PIMD: 24311149.

10. European Medicines Agency. Yescarta [Internet]. 2018 [cited 2019 Jun 10]. Available from:

11. United State Food and Drug Administration. YESCARTA (axicabtagene ciloleucel) [Internet]. Silver Spring MD: U.S. FDA; 2018 [cited 2019 Jun 10]. Available from:

12. Gionet-Gonzales MA, Leach JK. Engineering principles for guiding spheroid function in the regeneration of bone, cartilage, and skin. Biomed Mater 2018;13(3):1-27. doi: 10.1088/1748-605X/aab0b3. PMID: 29460842.

13. European Medicines Agency. Maci: matrix applied characterized autologous cultured ahondrocytes [Internet]. Amsterdam: Agency; 2013 [cited 2019 Jun 10]. Available from:

14. United State Food and Drug Administration. Maci: autologous cultured chondrocytes porcine collagen membrane [Internet]. Silver Spring MD: U.S. FDA; 2019 [cited 2019 Jun 10]. Available from:

15. Zur S. ATMPs: how to successfully master challenges and foster the regulatory success rate?. Corpus 2016;18:132-39.

16. Hunsberger J, Harrysson O, Shirwaiker R, Starly B, Wysk R, Cohen P, et al. Manufacturing road map for tissue engineering and regenerative medicine technologies. Stem cells transl med 2015;4:130-5.

17. Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ res 2015;116:12-5.

18. Wang K, Liu Y, Li J, Wang B, Bishop R, White C, et al. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy 2019;21:1081-93.

19. Mark W Lowdell, Owen Bain. Supply chain management in the delivery of ATMPs for trials and as licensed medicines. Cell Gene Therapy Insights 2017;3:843-51.

20. Hourd P, Chandra A, Medcalf N, Williams DJ, Regulatory challenges for the manufacture and scale-out of autologous cell therapies. 2014 Mar 31. In: StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008. doi: 10.3824/stembook.1.96.1. PIMD: 24851305.